论文部分内容阅读
目的:探讨VEGF、PCNA和P53在非小细胞肺癌(NSCLC)中的表达及其生物学行为的关系。方法:采用免疫组织化学方法,对病理确诊的62例非小细胞肺癌组织进行VEGF、PCNA和P53表达的检测。结果:62例非小细胞肺癌VEGF阳性表达率58.1%(36/62),其表达与NSCLC的组织分化程度、生存期有相关性(P<0.05),与组织学类型、有无淋巴结转移、临床病理分期无关。P53阳性表达率46.8%(29/62),表达与肿瘤组织类型、TNM分期、有无淋巴结转移无关(P<0.05)。PCNA阳性表达率61.0%(36/59),表达与肿瘤组织类型、TNM分期、有无淋巴结转移无关,与组织分化程度及生存期有关(P<0.05)。结论:VEGF、PCNA和P53可作为评价非小细胞肺癌预后的重要指标。
Objective: To investigate the relationship between the expression of VEGF, PCNA and P53 in non-small cell lung cancer (NSCLC) and their biological behavior. Methods: Immunohistochemistry was used to detect the expression of VEGF, PCNA and P53 in 62 non-small cell lung cancer tissues. Results: The positive expression rate of VEGF in 62 cases of non-small cell lung cancer was 58.1% (36/62), which was correlated with the degree of differentiation and survival of NSCLC (P <0.05), but not with the histological type, lymph node metastasis, Clinicopathological stage has nothing to do. The positive expression rate of P53 was 46.8% (29/62). The expression of P53 was not associated with tumor type, TNM stage and lymph node metastasis (P <0.05). The positive expression rate of PCNA was 61.0% (36/59). The expression of PCNA was correlated with tumor type, TNM stage and lymph node metastasis (P <0.05). Conclusion: VEGF, PCNA and P53 can be used as an important index to evaluate the prognosis of non-small cell lung cancer.